These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7678553)

  • 21. Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides.
    Germer M; Kanse SM; Kirkegaard T; Kjøller L; Felding-Habermann B; Goodman S; Preissner KT
    Eur J Biochem; 1998 May; 253(3):669-74. PubMed ID: 9654064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasmin can reduce the function of human beta2 glycoprotein I by cleaving domain V into a nicked form.
    Ohkura N; Hagihara Y; Yoshimura T; Goto Y; Kato H
    Blood; 1998 Jun; 91(11):4173-9. PubMed ID: 9596664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific binding of plasminogen to vitronectin. Evidence for a modulatory role of vitronectin on fibrin(ogen)-induced plasmin formation by tissue plasminogen activator.
    Preissner KT
    Biochem Biophys Res Commun; 1990 May; 168(3):966-71. PubMed ID: 1693270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts.
    Zhong J; Yang HC; Kon V; Fogo AB; Lawrence DA; Ma J
    Lab Invest; 2014 Jun; 94(6):633-44. PubMed ID: 24687120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limited proteolysis of vitronectin by plasmin destroys heparin binding activity.
    Sane DC; Moser TL; Greenberg CS
    Thromb Haemost; 1991 Sep; 66(3):310-4. PubMed ID: 1720904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
    Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
    Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1.
    Mimuro J; Kaneko M; Murakami T; Matsuda M; Sakata Y
    Biochim Biophys Acta; 1992 Dec; 1160(3):325-34. PubMed ID: 1477106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.
    Moser TL; Enghild JJ; Pizzo SV; Stack MS
    Biochem J; 1995 May; 307 ( Pt 3)(Pt 3):867-73. PubMed ID: 7537960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural and functional characterization of vitronectin-derived RGD-containing peptides from human hemofiltrate.
    Ständker L; Enger A; Schulz-Knappe P; Wohn KD; Germer M; Raida M; Forssmann WG; Preissner KT
    Eur J Biochem; 1996 Oct; 241(2):557-63. PubMed ID: 8917456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
    Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
    Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.
    Blouse GE; Dupont DM; Schar CR; Jensen JK; Minor KH; Anagli JY; Gårdsvoll H; Ploug M; Peterson CB; Andreasen PA
    Biochemistry; 2009 Mar; 48(8):1723-35. PubMed ID: 19193026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
    Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
    Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.
    Royle G; Deng G; Seiffert D; Loskutoff DJ
    Anal Biochem; 2001 Sep; 296(2):245-53. PubMed ID: 11554720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.
    Jensen JK; Malmendal A; Schiøtt B; Skeldal S; Pedersen KE; Celik L; Nielsen NC; Andreasen PA; Wind T
    Biochem J; 2006 Nov; 399(3):387-96. PubMed ID: 16813566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin.
    Ehrlich HJ; Keijer J; Preissner KT; Gebbink RK; Pannekoek H
    Biochemistry; 1991 Jan; 30(4):1021-8. PubMed ID: 1703436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Regulation of PAI-1 expression].
    Wyrzykowska P; Kasza A
    Postepy Biochem; 2009; 55(1):46-53. PubMed ID: 19514465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin.
    Naski MC; Lawrence DA; Mosher DF; Podor TJ; Ginsburg D
    J Biol Chem; 1993 Jun; 268(17):12367-72. PubMed ID: 7685341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor.
    Egelund R; Rodenburg KW; Andreasen PA; Rasmussen MS; Guldberg RE; Petersen TE
    Biochemistry; 1998 May; 37(18):6375-9. PubMed ID: 9572853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin.
    Seiffert D; Loskutoff DJ
    J Biol Chem; 1991 Feb; 266(5):2824-30. PubMed ID: 1704366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.